Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates
- 890 Downloads
Vancomycin-resistant enterococci (VRE) are of ever-increasing importance, most notably in high-risk patient populations. Therapy options are often limited for these isolates, and apart from tigecycline and daptomycin, oxazolidinone linezolid is frequently administered. The broad usage of linezolid, however, has driven the emergence of linezolid-resistant VRE strains (LR-VRE), further shortening therapeutic options. Second-generation oxazolidinone tedizolid has the advantage of being active against a specific subset of LR-VRE, i.e. isolates expressing the plasmid-encoded chloramphenicol–florfenicol resistance (cfr) gene. Here we tested tedizolid activity in a collection of 30 LR Enterococcus faecium VRE (MIC range 32–256 mg/l) isolated between 2012 and 2015 from clinical and screening specimens. By pulsed field gel electrophoresis (PFGE) isolates were assigned to 16 clonal lineages. In three cases, linezolid-susceptible progenitor isolates of LR-VRE were isolated, thus demonstrating the de-novo emergence of the linezolid-resistant phenotype. PCR did not detect cfr, cfr(B) or novel oxazolidinone resistance gene optrA in LR-VRE. All isolates, however, carried mutations within the 23S rDNA. Compared to linezolid, tedizolid MICs were lower in all isolates (MIC range 2–32 mg/l), but remained above the FDA tedizolid breakpoint for E. faecalis at 0.5 mg/l. Thus, related to the predominant resistance mechanism, tedizolid is of limited value for treatment of most LR-VRE and represents a therapeutic option only for a limited subset of isolates.
KeywordsLinezolid Daptomycin Tigecycline Florfenicol Linezolid Resistance
Compliance with ethical standards
MSD partially provided reagents used in this study.
Conflict of interest
None to declare.
Ethical approval/informed consent
- 7.Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ et al (2015) Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium isolates recovered from human specimens in the United States as part of the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 59(10):6256–6261CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z et al (2015) A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother 70(8):2182–2190CrossRefPubMedGoogle Scholar
- 16.Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ et al (2015) Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 81(2):112–118CrossRefPubMedGoogle Scholar
- 21.Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR et al (2001) Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 45(7):2154–2156CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Bourgeois-Nicolaos N, Nguyen TT, Defrance G, Massias L, Alavoine L, Lefort A et al (2014) The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics. Antimicrob Agents Chemother 58(5):2681–2687CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G (2014) Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone. Ann Clin Microbiol Antimicrob 13:46. doi: 10.1186/s12941-014-0046-0.:46-0046 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Fiedler S, Bender JK, Klare I, Halbedel S, Grohmann E, Szewzyk U et al (2016) Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M). J Antimicrob Chemother 71(4):871–881CrossRefPubMedGoogle Scholar